Artificial intelligence (AI) is one of the most incredible advanced technologies that use computerized algorithms to analyze complex data. AI-enabled Imaging Modality is an approach to achieve an accurate and correct diagnosis of patients to provide them with better and personalized treatment. It further helps identify imaging abnormalities and enhance tissue-based detection & characterization.
According to the MarkNtel Advisors’ research report, “Global Artificial Intelligence (AI) Enabled Imaging Modalities Market Analysis, 2021,” the market is likely to grow at a CAGR of around 31% during 2021-26 due to the rising workload of radiologists and surging complexities in clinical decision making. These challenges increase physicians' inclination toward adopting advanced technologies, including Artificial Intelligence, for better diagnosis and treatment. Further, rising security & privacy concerns regarding healthcare data also fuel the growth of the AI-enabled Imaging Modalities Market.
|Study Period||Historical Data: 2016-19|
|Base Year: 2020|
|Forecast Period: 2021-26|
|Regions Covered||North America: USA, Canada|
|Europe: Germany, UK, France, Russia|
|Asia-Pacific: China, India, Japan|
|South America: Brazil|
|Middle East & Africa: UAE, Israel|
|Key Companies Profiled||Arterys, Voxel cloud, Butterfly network, Infervision, Gauss Surgical, Owkin, Zebra Medical Vision, Curemetrix, Cellmatiq, MedyMatch, BrainerMiner, Lunit|
|Unit Denominations||USD Million/Billion|
Impact of COVID-19
The outbreak of the global COVID-19 pandemic has brought out a revolution in the Global AI-Enabled Imaging Modalities Market. Due to the pandemic, the AI-Enabled Imaging Modalities Market has witnessed a positive impact due to the rising awareness and surging adoption of digital healthcare solutions. Additionally, AI is highly beneficial for gaining insights & proper diagnosis that can help find a solution to fight disease transmission at early stages. Hence, this incredibly advanced technology is likely to be extensively used for fighting the COVID-19 pandemic.